C
Cathy Malcontenti-Wilson
Researcher at University of Melbourne
Publications - 9
Citations - 152
Cathy Malcontenti-Wilson is an academic researcher from University of Melbourne. The author has contributed to research in topics: In vivo & Pirarubicin. The author has an hindex of 6, co-authored 9 publications receiving 147 citations.
Papers
More filters
Journal ArticleDOI
Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases.
Jurstine Daruwalla,Khaled Greish,Cathy Malcontenti-Wilson,Vijayaragavan Muralidharan,Arun K. Iyer,Hiroshi Maeda,Christopher Christophi +6 more
TL;DR: SMA-pirarubicin damages tumor cells and the tumor microvasculature and enhances tumor vessel permeability, but tumor necrosis is incomplete, and the growth of residual cells is sustained by a microvascular network.
Journal ArticleDOI
Interstitial laser hyperthermia for colorectal liver metastases: the effect of thermal sensitization and the use of a cylindrical diffuser tip on tumor necrosis.
TL;DR: Diffuser-tipped optical fiber appears to significantly increase the diameter of ILH-induced tumor necrosis compared to the bare fiber, in contrast to thebare fiber, which enables the application of laser energy using higher power settings without compromising theiameter of tumor Necrosis achieved.
Journal ArticleDOI
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo
Christopher J. Burns,Emmanuelle Fantino,Ian D Phillips,Stephen Su,Michael Francis Harte,P. Bukczynska,Mark Frazzetto,Max Joffe,Irma Kruszelnicki,Bing Wang,Yue Wang,Neil Wilson,Rodney J. Dilley,Soo San Wan,Susan A. Charman,David M. Shackleford,Rosa Fida,Cathy Malcontenti-Wilson,Andrew F. Wilks +18 more
TL;DR: CYT997 is a wholly synthetic compound that possesses highly potent cytotoxic activity in vitro through inhibition of microtubule polymerization and has considerable potential as a novel anticancer agent.
Journal ArticleDOI
Physiological characterization of a mouse model of cachexia in colorectal liver metastases
TL;DR: Findings reveal the MoCR mouse model exhibits significant cachexia and is a suitable preclinical model of cachexia in colorectal liver metastases, which should be used for identifying effective treatments for cachexia to improve quality of life and reduce mortality in patients with coloreCTal liver cancer metastases.
Journal ArticleDOI
Alterations in vascular architecture and permeability following OXi4503 treatment.
TL;DR: The findings suggest that O Xi4503 selectively targets tumor vessels and causes immediate microvascular destruction, and a combination of OXi4503 with other chemotherapeutic modalities might achieve complete tumor eradication and improve long-term survival.